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co-morbid disorders. Literature from the UK and 
Netherlands report a delay between ﬁrst contact with a
GP and diagnosis ranging from months to years. One UK
report found that many general practitioners were skep-
tical of ADHD and that parents felt rebuked by the GP
when they ﬁrst presented a hyperactive pre-school child.
One FR speciﬁc report found that of those referred, 62%
had not received any previous medical advice. CON-
CLUSION: Diagnosis may be hindered by co-morbid dis-
orders, GP skepticism of hyperactivity as a behavioural
disorder, and parents feeling they are not taken seriously.
Once recognised as having an emotional/behavioural
problem, referral to a specialist is unlikely resulting in 
signiﬁcant delays between ﬁrst contact with a GP and
diagnosis/treatment. Hence, some sufferers, especially
females, may not be diagnosed.
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OBJECTIVES: To improve quality and persistency of
anti-depressive therapy in primary care by a correspon-
dence course for GPs focusing on interaction between
patient and physician. METHODS: One hundred sixty-
nine depressive patients in two groups were observed in
a cohort study. GPs in the education group (84 patients)
received training material on therapy of depression. A
parallel control group of 85 depressive patients recruited
by physicians not obtaining training material was
observed to compare effectiveness. In both groups
patients were on Citalopram treatment. Measures: 
demographics, prescriptions, Clinical Global Impression
Scale (CGI) and Hamilton Depression Scale (HAM-D).
Additionally, patients were asked to answer questions
concerning their treatment satisfaction and quality of life
(SF-36). They were observed over a 6-month period. For
external comparison of therapy duration to non-study
conditions, data from the prescription database MediPlus
(IMS HEALTH) were analysed. RESULTS: Comparing
the two groups there were no differences in clinical data
(CGI, HAM-D) and quality of life (SF-36). However, the
following differences were found: In comparison to
control group, patients in education group had more con-
tacts to their GP. Especially in the beginning of therapy,
there were shorter intervals between visits. Patients in
education group received anti-depressive medication for
a longer period. In education group the rate of discon-
tinuing the pharmaceutical therapy within the recom-
mended 6-month period was only 36% in comparison to
44% in the control group (reduction of 18%). When
related to MediPlus data, the discontinuation rate was
lowered by 46%. CONCLUSIONS: The IMPROVE-D
training material for GPs improved therapy quality and
persistency. The training resulted in more frequent physi-
cian contacts and careful drug prescription. Patients 
felt more bound to the physician’s instructions and
showed a better compliance. This resulted in a longer
therapy duration which experts link to a reduced risk for
relapsing.
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Published models for schizophrenia in literature are 
generally Markov models, which entail many methodo-
logical disadvantages. OBJECTIVE: To build a disease
progression model for schizophrenia that circumvents the
problems of Markov modelling. The model is designed to
simulate individual histories of schizophrenic patients
from the age of onset until death, but it can easily be
adapted to shorter time horizons. A patient enters the
model when he visits the psychiatrist because he suffers
from a relapse. At each visit the psychiatrist will re-
evaluate the visiting scheme, the patient’s treatment and
his location. Furthermore, the psychiatrist will estimate
the patient’s severity of disease (PANSS, QALY, Danger).
At any time the patient can decide to be non-compliant.
METHODS: The model is characterised by four steps: 1)
deﬁnition and description of patient characteristics, 2)
calculation of the progression of schizophrenia for that
individual patient in each of the compared treatment
strategies, 3) calculation of the costs and effects generated
in each of the strategies; and 4) when previous steps are
performed for a speciﬁc patient population, calculation
of the average medical and economical outcomes per
strategy. RESULTS: The model is able to simulate indi-
vidual patient histories with patient-speciﬁc probabilities.
Unlike Markov models, we do not assume a direct link
between a health state and costs. Moreover, we individu-
alise the relations between what happens to a patient and
the expected costs and effects. Also, we take account 
of unobserved heterogeneity. CONCLUSIONS: The 
outlined model is complex and needs much input. 
Moreover, many estimates are surrounded by uncertain-
ties. However, it needs to be stressed that simpler models
implicitly need the same input, but they hide assumptions
that are explicit in this model. Therefore, the presented
model is subtler, more transparent and closer to clinical
practice.
